Lymphoma

The treatment landscape for relapsed or refractory indolent non-Hodgkin lymphoma continues to shift from chemoimmunotherapy to targeted treatments, according to a speaker at Chemotherapy Foundation Symposium.

A greater proportion of patients with cutaneous T-cell lymphoma and sepsis were older, Black and experienced more sepsis episodes compared with patients with sepsis and a different type of non-Hodgkin lymphoma, according to a study.

The addition of first-line brentuximab vedotin to chemotherapy reduced risk for relapse compared with standard treatment among pediatric patients with high-risk Hodgkin lymphoma, according to study results.

Follicular lymphoma is among the least common types of non-Hodgkin lymphoma, but the nature of the disease has allowed those who require treatment to benefit from the groundbreaking development of chimeric antigen receptor T cells.

An FDA advisory panel voted 8-4 that duvelisib did not have a favorable benefit-risk profile for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who received at least two prior therapies.

Gerontology researchers and hematologic oncology investigators from Brigham and Women’s Hospital and Dana-Farber Cancer Institute have devised a scale for assessing high-risk medications in older patients with blood cancers.

September is Childhood Cancer Awareness Month.

FDA issued a safety alert Thursday regarding reports of squamous cell carcinoma and various lymphomas in the scar tissue surrounding breast implants.

Rates for CV admissions among patients with cancer has increased, according to a study published in the European Heart Journal Quality of Care & Clinical Outcomes.Primary CV admissions are highest among patients with hematological cancer with the most common cause of admission being heart failure, according to the study.

Luis E. Malpica Castillo, MD, of The University of Texas MD Anderson Cancer Center received the ASH-Harold Amos Medical Faculty Development Program Award.